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Abstract
Background: Methadone maintenance treatment programs (MMTPs) are important public health intervention to
control the human immunodeficiency virus (HIV) and the drug use problems. For expanding treatment coverage,
publicly funded programs may be necessary for heroin users with low socio-economic status. We evaluated the
difference of demographics, clinical features, and quality of life (QoL) of heroin users enrolled in publicly funded and
self-paid MMTP and explored determinants influencing their attendance rate, respectively, for these two groups.
Methods: A total of 234 heroin users enrolled in MMTP (129 in publicly funded and 105 in self-paid) between 2006
and 2008 self-reported the Taiwan version of the World Health Organization Quality of Life Instrument, Brief Version
(WHOQOL-BREF) at baseline. Data regarding demographic and clinical features were collected during baseline
interview. Methadone per 3-month attendance rates up to 18 months were conducted for each participant beginning
from the index date.
Results: Self-paid group had a better QoL but lower treatment adherence than did the publicly funded group. Male
and living alone were positive predictors on attendance rate for publicly funded group, and age of first heroin use and
hepatitis C virus (HCV) seropositive were negative predictors. However, predictors on attendance rate for self-paid
group were different from publicly funded group: HCV seropositive was a positive predictor and social QoL was a
negative predictor.
Conclusions: Findings of this study should be concerned with modifying original funding eligibility. Additional
measures to explore what could impede treatment adherence are needed.
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Background
Taiwan implemented a National Health Insurance (NHI)
program from March 1995, offering a comprehensive,
unified, and universal health insurance program to all
citizens [1]. The coverage includes outpatient service, in-
patient care, Chinese medicine, dental care, childbirth,
physical therapy, preventive health care, home care, and
rehabilitation for chronic mental illness. In addition, the
NHI program covers as high as 99 % of Taiwan population
[2]. However, the cost on items directly related to sub-
stance use, such as the methadone maintenance treatment
(MMT), is not covered by the NHI. MMT is a primary
treatment for opioid-dependent people who have signifi-
cantly elevated mortality than their general counterparts
[3], and opioid dependence makes global disease a burden
[4]. Although numerous studies [5–9] report that MMT
has encouraging results of reducing drug addiction, de-
creasing illegal activities, and improving the overall well-
being for drug users, the MMT program (MMTP) was
not permitted until 2006: The Taiwan Center for Disease
Control (CDC) permitted MMTP for patients with opioid
dependence in response to human immunodeficiency
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virus (HIV) epidemic [10]. Several publicly funded
MMTPs were held due to the urge for inhibition of the
HIV infection spread. The criteria of participating in a
publicly funded MMTP were that the heroin users were
HIV seropositive, ex-prisoners, or applying for deferred
prosecution. The publicly funded MMTP provided free
treatment for heroin users with HIV seropositive and
1-year service without payment for those who applied
for deferred prosecution or who were ex-prisoners.
However, those heroin users who did not fulfill the
publicly funded criteria were charged around 100 US$
per month for the treatment (self-paid MMTP). Previ-
ous American studies [11, 12] found that Medicaid eligi-
bility was strongly associated with enrollment in MMTP,
and Medicaid clients had far greater access to MMTP
than non-Medicaid counterparts after controlling their
characteristic differences. However, studies with regard to
differences between publicly funded and self-paid MMTP
have been minimally addressed, especially in the East.
As for comparing the publicly funded and self-paid
MMTP, we recommend using an important outcome
index, quality of life (QoL). QoL refers to a subjective
evaluation which is embedded in a cultural, social, and
environmental context [13]. There were increasing evi-
dences that a good QoL is associated with a better treat-
ment outcome in patients with opioid dependence, e.g.,
[14, 16]. In addition, research has found that co-morbid
infectious disease such as HIV and hepatitis C virus
(HCV) and drug-related crimes which are frequent in
heroin users may impair their QoL [15–17]. Therefore,
understanding the QoL and features of the two MMTP
groups may provide clinicians useful information and
help them make a critical clinical decision.
In addition to the QoL, adherence is another import-
ant issue for MMTP participants. Several studies from
the West [18–21] found that high methadone adherence
is necessary for successful therapeutic outcomes. Fur-
thermore, these studies [18–21] used retention rate as an
index to represent the adherence. However, if the policy
provides no take-home dose for methadone maintenance
patients (e.g., the MMTP in Taiwan), we suggested that
treatment attendance, another adherence index, becomes
essential for understanding treatment effectiveness. Suc-
cessful MMT requires both long-term enrollment (reten-
tion duration) at an adequate dosage and on daily basis
(regular attendance) [9]. In addition, to the best of our
knowledge, studies reporting the factors influencing on
methadone adherence in Asia are still scarce. Therefore, in-
vestigating the factors that influence on MMTP attendance
rate in an East-Asian country (say, Taiwan) is necessary.
Using an 18-month follow-up data from one psychiatric
center in south Taiwan, this observational study aimed to
(1) examine the QoL difference between methadone
maintenance patients presented for publicly funded and
self-paid MMTP and (2) explore determinants influencing




A retrospective cohort study was conducted, and all re-
cruited participants between March 2006 and July 2008
were diagnosed as opioid dependence by a board-
certified psychiatrist from the Jianan Psychiatric Center
research team. The inclusion criteria were as follows: (1)
being more than 20 years old; (2) meeting the DSM-IV
(Diagnostic and statistical manual of mental disorders,
fourth edition) criteria for opioid dependence; (3) having
sufficient mental competence to understand and sign an
informed consent; (4) residing near our treatment ser-
vice site (i.e., Tainan City); and (5) no other MMTP
contraindication, such as severe liver cirrhosis, severe
cognitive impairment, or behavioral disturbances. None
of the participants had participated in any MMTP before
the intake interview. At the intake interview, the partici-
pants were identified as publicly funded MMTP (n = 129)
or self-paid MMTP (n = 105) groups based on whether
they met the publicly funded eligibility criteria: (a) as a
function of HIV status; (b) applying for deferred prosecu-
tion; and (c) had been incarcerated due to the Drug Act
before and discharged during the recruited period. Metha-
done attendance of 18 months was conducted for each
participant from the index date, and we divided the study
period into six phases of 3 months duration each. The
Hospital Ethics Committee of Jianan Psychiatric Center
approved this study (IRB number, JMH9601).
Quality of life
We used the World Health Organization Quality of Life
Assessment, Brief Version (WHOQOL-BREF), which con-
tains 28 items with 26 standard items from the original
WHOQOL-BREF, and two Taiwanese national items [22].
In addition, the WHOQOL-BREF Taiwan version includes
four domains (physical, seven items; psychological, six
items; social, four items, and environment, nine items)
and two generic items which did not belong to any do-
main (“overall QoL” and “general health”). Domain
scores are calculated into a 4-to-20 range, and a higher
score represents a better QoL. Moreover, the psycho-
metric properties of WHOQOL-BREF are satisfactory
in Taiwan population [22], including those with a men-
tal illness [23–25].
Demographics and lab tests
In addition to the WHOQOL-BREF, each MMTP patient
completed a background information sheet including his
or her birth date, gender, living status (alone vs. with
others), educational years, age of first heroin use, heroin
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using years, employment status (fixed or not), and family
drug using. After completing the WHOQOL-BREF and
the background information sheet, each patient under-
went a series of laboratory tests, including HIV, HBV,
and HCV tests.
Data analysis
Baseline characteristics and QoL scores between publicly
funded and self-paid MMTP groups were compared
using χ2 tests (for frequency comparisons) and inde-
pendent t tests (for mean comparisons). In addition,
QoL scores of the two groups were separately compared
with QoL scores of Taiwan population using one-sample
t tests. The mean (±SD) QoL scores of Taiwan popula-
tion are 14.06 ± 2.34 for the physical, 13.23 ± 2.15 for the
psychological, 13.56 ± 2.29 for the social, and 12.72 ±
2.07 for the environment domains [26].
Generalized estimating equation (GEE) was used to
examine the effects of several predictors on attendance
rate. Because each participant had one to six attendance
rates (i.e., the attendance rates for 3, 6, 9, 12, 15, and
18 months) from participating in the MMT program to
18 months later, using the GEE is adequate. All the ana-
lyses were done using SPSS 15.0 (SPSS Inc., Chicago,
IL.).
Results
No significant differences were found between the pub-
licly funded and self-paid MMTP participants in their
demographic data, except for heroin using years (t =
3.59, P < 0.001) and HIV carrier (χ2 = 45.35, P < 0.001).
The publicly funded group had significantly more heroin
using years (9.25 ± 6.77 vs. 6.48 ± 3.86) and HIV carriers
(n = 45 vs. 0) than the self-paid group. In addition, the
self-paid MMTP participants had significantly higher
QoL scores than the publicly funded MMTP participants
in all QoL domains (Table 1).
As compared with Taiwan population, the publicly
funded MMTP participants had all but the environment
domain scores significantly lower than the scores of
Taiwan population. In addition, the self-paid MMTP
participants had significantly lower QoL score in the
physical domain and higher score in the environment
domain (Table 2).
Different predictors of attendance rate were found be-
tween publicly funded and self-paid groups. Significant
predictors for the publicly funded group were gender
(reference = female; β = −0.115, P < 0.05), living alone
(reference = no; β = 0.088, P < 0.01), age of first heroin
use (β = −0.007, P < 0.05), and HCV carriers (reference =
seronegative; β = −0.068, P < 0.05). As for the self-paid
group, significant predictors were HCV carriers (refer-
ence = seronegative; β = 0.224, P < 0.01) and social QoL
scores (β = −0.020, P < 0.05) (Table 3).
Discussion
Our results are consistent with previous studies: heroin
users had lower QoL scores as compared with the gen-
eral population [27]. This also echoes the findings in
other research that heroin users often find themselves in
a crisis situation at the MMTP intake and attend treat-
ment in poor condition, resulting in low QoL scores at
admission [28, 29]. However, unlike the publicly funded
group who had all domains of QoL but environment
QoL significantly lower than the Taiwan general popula-
tion, the self-paid group only had its physical QoL lower
than the Taiwan general population. One possible ex-
planation is that the eligibility of free treatment covered
heroin users who contracted HIV or applying for de-
ferred prosecution make the reasons of seeking treat-
ment different. Although our treatment modality only
provided methadone maintenance, we hypothesized that
self-paid heroin users choose to attend MMTP mainly
for their physical discomfort suffering, especially the her-
oin withdrawal syndrome. This hypothesis may corres-
pond with one study in China that reported that
MMTP-related misconception (e.g., one could be com-
pletely detoxified and quit methadone treatment for the
coming months) are very common among newly admit-
ted first-time participants and misconception found at
admission of MMTP predicted subsequent dropout dur-
ing the treatment period [30]. That is, the heroin users
dropped out the MMTP when they released their phys-
ical pain. In addition, a much higher retention rate of
our publicly funded group than that of the self-paid
group (18 months retention rate was 31.0 % for publicly
funded and 11.0 % for the self-paid group) may also in-
directly support our hypothesis. Further investigation
regarding the perception and opinion toward MMTP
among heroin users in Taiwan are also needed.
We found no demographic differences between heroin
users under coverage of publicly funded and those of
self-paid MMTP. However, QoL among publicly funded
methadone patients was even worse. Although there was
no demographic disparity between the publicly funded
and self-paid MMTP, the publicly funded group had lon-
ger heroin abusing length and more HIV-seropositive
patients than the self-paid group. This may explain the
lower QoL (including physical, psychological, social, and
environment QoL) of the publicly funded group than
that of the self-paid group. Previous studies indicate that
people who have longer heroin use or who are HIV sero-
positive are more likely to have worse health status and
QoL than their counterparts with shorter heroin use or
HIV seronegative [14, 17].
The most interesting finding is that predictors for
MMTP attendance rate were different between publicly
funded and self-paid groups. Our results of educational
years and employment status as non-significant
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predictors are comparable to previous studies [31–34].
However, our results of gender as a significant predictor
for publicly funded group contradict other research’s
findings [31–34]. The most possible reason is the differ-
ence between publicly funded and self-paid groups. We
pooled all the participants and redid a GEE analysis, and
our results showed that gender cannot significantly pre-
dict attendance rate in the pooled sample (β = −0.054,
95 % CI = −0.124 to 0.016, P = 0.133). Gender difference
of attendance pattern in our publicly funded group echo
another recent finding [35] that persistent drug-related
stigmatization paired with HIV-related discrimination
among male heroin users hindered their employment
and exacerbated their struggles with addiction. Although
our publicly funded male participants remained on treat-
ment, their low socio-economic status often forced them
to struggle between job and regular attendance.
In addition to the demographic factors mentioned
above, good social QoL and HCV seropositive were good
predictors for worse and better methadone attendance,
respectively, in our self-paid group. The negative influ-
ence of social QoL on the attendance rate could be ex-
plained by the misconception toward MMTP among
their peer group, though we did not have solid evidences
to justify this explanation, and future studies are war-
ranted. Another explanation for the negative influence
Table 1 The baseline characteristics and QoL scores comparisons using independent t tests (for continuous variables) or χ2 tests
(for categorical variables) between publicly funded and self-paid methadone maintenance treatment patients
Publicly funded Self-paid χ2 or t P
n Mean (SD) n Mean (SD)




Living alonea 1.99 0.158
No 118 98
Yes 11 4
Educational years 129 9.36 (2.55) 105 9.48 (2.09) 0.40 0.688
Age of first heroin use 129 25.59 (5.89) 105 26.92 (6.80) 1.65 0.101
Heroin using yearsa 112 9.25 (6.77) 82 6.48 (3.86) 3.59 <0.001
Fixed employmenta <0.01 0.975
No 60 49
Yes 68 56
Family drug using 0.47 0.495
No 109 92
Yes 20 13
HBV carrier 0.28 0.597
Seronegative 106 89
Seropositive 23 16
HCV carrier 3.30 0.069
Seronegative 4 9
Seropositive 125 96
HIV carrier 45.35 <0.001
Seronegative 84 105
Seropositive 45 0
Physical QoLa 128 11.95 (1.89) 103 12.48 (1.94) 2.10 0.036
Psychological QoL 129 11.94 (2.68) 105 12.83 (2.12) 2.83 0.005
Social QoLa 129 12.62 (3.12) 104 13.44 (2.80) 2.09 0.038
Environment QoL 129 12.47 (2.86) 105 13.43 (2.30) 2.77 0.006
QoL quality of life, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus
aWith missing values
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could be the good social interaction in the self-paid
group. With good social interaction, the self-paid group
tended to receive heroin from their friends and became
less motivated to take methadone. On the other hand, the
positive impact of HCV seropositive may be due to the
prevalence and awareness of the self-paid patients. Metha-
done patients are found to have high prevalence but low
awareness of HCV infection while attending MMTP [36],
and their motivation to regular attendance would be en-
hanced through psycho-education and counseling. In con-
trast to the self-paid group, however, HCV seropositive had
a negative influence on attendance rate of the publicly
funded participants. However, because HIV infection was a
covariate in the GEE model for the publicly funded group,
a possibility was that the effect of HCV infection influenced
by that of HIV infection. In order to clarify the role of HCV
infection in the publicly funded group, we additionally did
a GEE model without the covariate of HIV for the publicly
funded group, and a similar result was found (β = −0.068,
P = 0.012). Therefore, we tentatively concluded that at-
tendance pattern could be different between methadone
patients contracted HCV and co-morbid HIV-HCV infec-
tion. However, certain baseline variables found to have an
effect on the self-paid group used to predict attendance
rate may have little effect on the publicly funded MMTP
group. Further studies to examine the disparity between
heroin users attending publicly funded and self-paid
MMTP are urgently needed for policy makers.
Although our results shed some light on the issues of
QoL and treatment adherence for heroin users engaging
in a MMTP, clinicians should interpret our results, in-
cluding those in Tables 1, 2, and 3, in cautions because
the two MMTP groups consisted of different baselines.
In addition, clinicians should also understand that the
publicly funded MMTP patients in Taiwan were quite
different from those in the USA: the publicly funded
Table 3 Predictors of attendance rate on the heroin-dependent individuals receiving methadone maintenance treatment using
generalized estimating equation models
Attendance rate (3, 6, 9, 12, 15, and 18 months)
Publicly funded Self-paid
β (95 % CI) β (95 % CI)
Age (year) 0.005 (−0.001, 0.010) 0.001 (−0.004, 0.006)
Gender (ref: female) −0.115* (−0.216, −0.013) −0.017 (−0.101, 0.066)
Living alone (ref: no) 0.088** (0.024, 0.152) 0.023 (−0.111, 0.156)
Educational years −0.005 (−0.001, 0.010) −0.013 (−0.026, <0.001)
Age of first heroin use −0.007* (−0.012, −0.001) <0.001 (−0.006, 0.005)
Fixed employment (ref: no) −0.002 (−0.055, 0.051) 0.053 (−0.004, 0.111)
Family drug using (ref: no) 0.046 (−0.016, 0.107) 0.026 (−0.074, 0.125)
HBV (ref: seronegative) −0.015 (−0.093, 0.063) 0.026 (−0.062, 0.113)
HCV (ref: seronegative) −0.068* (−0.120, −0.016) 0.224** (0.085, 0.363)
HIV (ref: seronegative) 0.009 (−0.051, 0.069) –a –a
Physical QoL −0.015 (−0.034, 0.004) 0.022 (−0.001, 0.045)
Psychological QoL −0.010 (−0.025, 0.006) −0.011 (−0.031, 0.009)
Social QoL −0.002 (−0.017, 0.013) −0.020* (−0.034, −0.006)
Environment QoL 0.012 (−0.003, 0.028) 0.019 (−0.001, 0.039)
QoL quality of life, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus
*P < 0.05, **P < 0.01, ***P < 0.001
aNo values due to no HIV patients in this model
Table 2 Comparisons using one-sample t tests between
methadone maintenance treatment patients and Taiwan
population
Publicly funded Self-paid
Physical QoL n 128 103
Mean (SD) 11.95 (1.89) 12.48 (1.94)
t (P) −12.66 (<0.001)a −8.25 (<0.001)a
Psychological QoL n 129 105
Mean (SD) 11.94 (2.68) 12.83 (2.12)
t (P) −5.45 (<0.001)b −1.93 (0.056)b
Social QoL n 129 104
Mean (SD) 12.62 (3.12) 13.44 (2.80)
t (P) −3.42 (0.001)c −0.43 (0.669)c
Environment QoL n 129 105
Mean (SD) 12.47 (2.86) 13.43 (2.30)
t (P) −0.98 (0.327)d 3.15 (0.002)d
aCompare with Taiwan population (mean ± SD = 14.06 ± 2.34)
bCompare with Taiwan population (mean ± SD = 13.23 ± 2.15)
cCompare with Taiwan population (mean ± SD = 13.56 ± 2.29)
dCompare with Taiwan population (mean ± SD = 12.72 ± 2.07)
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MMTP in Taiwan currently is a kind of (partly) compul-
sory legal act and is not comparable with that of the
Medicaid eligibility in the USA. Therefore, all publicly
funded MMTP patients in this study had the situations of
either with a legal issue or with HIV infection. In contrast,
the self-paid MMTP patients did not have the problems
that the publicly funded MMTP patients confronted. Thus,
the comparisons between the two groups may be inappro-
priate, and our results are highly likely to be biased.
The strength of this study was that newly admitted
MMTP participants with better retention were our par-
ticipants, while regular attendance could indicate better
treatment outcome only under the circumstance of long
enough treatment retention (e.g., 1-year retention). An-
other advantage is that our study collected two kinds of
important determinants (WHOQOL-BREF for measur-
ing generic QoL and blood sample for confirming the
chronic infectious disease) at baseline to predict attend-
ance rate up to 18 months.
However, this study has some limitations. First, our
study involved only one site, limiting the generalization
of its findings. Based on this limitation, readers need to
know that our comparison results between MMTP pa-
tients and Taiwan general population were biased. Sec-
ond, the study employed a cross-sectional design at the
intake interview and the attendance rate may be affected
by some potential important ongoing or time-dependent
factors. Although previous Taiwan study reported no sig-
nificant difference between HIV-positive and HIV-negative
methadone patients [37], it should still be interpreted with
caution because our publicly funded eligibility covered all
heroin users with HIV seropositive. In addition, our predic-
tors of QoL were time-dependent factors as well. Therefore,
the predictive ability of our proposed QoL factors is very
likely to be changed overtime, and the predicting effect of
QoL on attendance rates should be used in cautions. Third,
self-stigma [38, 39], another important factor that could im-
pact patients’ volition to attend MMT, was not measured in
this study. Future studies may want to use validated ques-
tionnaire, e.g., Internalized Stigma of Mental Illness Scale
[40] and Self-Stigma Scale-Short [41] to understand the im-
pact of self-stigma on attendance rate. Fourth, some co-
payment MMTPs which have had executed after the re-
cruited period might enhance the methadone adherence
among our self-paid group. Lastly, self-reported data were
used. Despite we guaranteed the privacy, reporting bias
may still exist.
Conclusions
To the best of our knowledge, this is the first study com-
paring the QoL between publicly funded and self-paid
heroin users and identifying their association of metha-
done attendance rate during 18 months follow-up.
MMT is undoubtedly the key public health measures to
control the HIV and the drug use problems. For treat-
ment to be effective, regular attendance is necessary for
reducing social costs in terms of drug-related legal and
medical expenses. Previous study [42] has reported that
drug users do not primarily associate QoL with health,
but rather with social inclusion and self-determination.
Under the circumstance of the impact of methadone
maintenance was very similar in these MMTPs, if partic-
ipants attend regularly. Measures to further explore what
could potentially impede methadone attendance are
needed. However, cautions are needed when clinicians
and/or researchers interpret our results due to the differ-
ent natures of our MMTP patients.
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